Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ

Arthritis and Rheumatism

Volumn 65, Issue 11, 2013, Pages 2954-2962

  Fiorentino, David F ^a   Chung, Lorinda S ^b   Christopher Stine, Lisa ^c   Zaba, Lisa ^a   Li, Shufeng ^a   Mammen, Andrew L ^c   Rosen, Antony ^c   Casciola Rosen, Livia ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR MATRIX PROTEIN; PROTEIN; PROTEIN ANTIBODY; TRANSCRIPTION INTERMEDIARY FACTOR 1GAMMA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODY DETECTION; ARTICLE; CHILD; DERMATOMYOSITIS; DISEASE ASSOCIATION; FEMALE; HELA CELL; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEX RATIO;

ADENOSINE TRIPHOSPHATASES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HELA CELLS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POL1 TRANSCRIPTION INITIATION COMPLEX PROTEINS; RADIOIMMUNOASSAY; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 84886802891     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38093     Document Type: Article

References (33)

1. Betteridge ZE, Gunawardena H, McHugh NJ,. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther 2011; 13: 209.
2. Casciola-Rosen L, Mammen AL,. Myositis autoantibodies. Curr Opin Rheumatol 2012; 24: 602-8.
3. Madan V, Chinoy H, Griffiths CE, Cooper RG,. Defining cancer risk in dermatomyositis: part I. Clin Exp Dermatol 2009; 34: 451-5.
4. Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012; 64: 513-22.
5. Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, et al, for the Juvenile Dermatomyositis Research Group, UK and Ireland. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60: 1807-14.
6. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 2010; 49: 433-40.
7. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60: 2193-200.
8. Targoff IN, Trieu EP, Levy-Neto M, Prasertsuntarasai T, Miller FW,. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-g) in dermatomyositis [abstract]. Arthritis Rheum 2006; 54 Suppl: S518.
9. Targoff IN, Trieu EP, Levy-Neto M, Fertig N, Oddis CV,. Sera with autoantibodies to the MJ antigen react with NXP2 [abstract]. Arthritis Rheum 2007; 56 Suppl: S787.
10. Chen F, Wang D, Shu X, Nakashima R, Wang G,. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int 2012; 32: 3909-15.
11. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L,. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 25-34.
12. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011; 147: 391-8.
13. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T,. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010; 49: 1726-33.
14. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571-6.
15. Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti-MDA5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013. E-pub ahead of print.
16. Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O'Callaghan A, Martinez-Gomez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64: 523-32.
17. Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, Ikezawa Z,. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol 2011; 38: 973-9.
18. Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee EB, et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010; 11: 223.
19. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG,. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007; 66: 1345-9.
20. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, et al, for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Groups. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682-9.
21. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, et al, and for the Juvenile Dermatomyositis Research Group UK. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47: 324-8.
22. Betteridge ZE, Gunawardena H, Chinoy H, Vencovsky J, Allard S, Gordon PA, et al. Autoantibodies to the p140 autoantigen NXP-2 in adult dermatomyositis [abstract]. Arthritis Rheum 2009; 60 Suppl: S304.
23. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 2012; 14: R97.
24. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012; 71: 710-3.
25. Ishikawa A, Muro Y, Sugiura K, Akiyama M,. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford) 2012; 51: 1181-7.
26. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV,. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009; 36: 2547-51.
27. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
28. Sontheimer RD,. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 2002; 20: 387-408.
29. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL,. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005; 84: 231-49.
30. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD,. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54: 597-613.
31. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Tincani A, et al. Anti-MJ/NXP-2 antibodies are the most common specificity in a cohort of adult Caucasian patients with dermatomyositis [abstract]. Arthritis Rheum 2011; 63 Suppl: S85-6.
32. Fiorentino D, Callen JP,. Dermatomyositis. In:, Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B, editors. Evidence-based dermatology. Oxford: Blackwell Publishing; 2008. p. 559-72.
33. Bendewald MJ, Wetter DA, Li X, Davis MD,. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010; 146: 26-30.